Point-of-care diagnostics—tests performed near a patient rather than in a central lab—are moving from a niche convenience to a major part of modern healthcare. The appeal is simple: instead of waiting hours or days for samples to be sent away, clinicians and patients can often get answers in minutes at the bedside, in a pharmacy, in a community clinic, or at home. That speed can change decisions on the spot, from whether someone needs treatment to whether they should seek follow-up care. The category is not brand new; home pregnancy tests and glucose meters have been familiar examples for decades. What has changed is the scale and sophistication of the technology, especially after the COVID-19 pandemic showed how useful rapid, distributed testing can be. Newer systems increasingly combine portable hardware, microfluidics—the controlled movement of tiny amounts of liquid through miniature channels—and smartphone software to make testing easier to use outside traditional labs. Market data cited by European Pharmaceutical Manufacturer suggests the business side is expanding quickly too, with global point-of-care diagnostics reaching $44.25 billion in 2023 and projected to grow to $80.75 billion within a decade. Taken together, the trend points to a healthcare model that is faster, more local, and more connected to digital tools than the lab-centered system many patients still think of first.
Why point-of-care testing is gaining ground
The core promise of point-of-care, often shortened to PoC, is immediacy. A conventional lab workflow is a bit like mailing a package across town and waiting for a return note; point-of-care testing is more like getting an answer at the counter before you leave.
That faster turnaround matters because many healthcare choices are time-sensitive. If a clinician can see a result during the same visit, they can decide on next steps right away instead of asking a patient to wait, return later, or fall through the cracks.
The pandemic changed expectations
PoC testing existed long before COVID-19, but the pandemic changed how widely people understood its value. Rapid tests became a public example of how diagnostics could move out of centralized laboratories and into homes, workplaces, and community settings.
That shift did more than normalize self-testing. It also raised expectations that healthcare information should be available quickly, at scale, and close to where people actually live and receive care.
What is driving market growth
European Pharmaceutical Manufacturer cites research from Nova One Advisor showing the global point-of-care diagnostics market at $44.25 billion in 2023, with a forecast of $80.75 billion over the next 10 years. That is a striking jump, and it suggests PoC tools are being treated as a durable part of healthcare infrastructure rather than a short-term trend.
The article points to several forces behind that growth: rapid advances in non-invasive products, self-testing, and digitally connected devices. It also ties demand to large demographic pressures, including an ageing global population and the rising prevalence of chronic diseases that require repeated monitoring rather than one-off hospital visits.
Smaller devices, smarter systems
One of the most important technical trends is the combination of compact testing hardware with digital platforms. Think of it as moving from a standalone gadget to a connected system: the test does not just produce a number, it can also capture, interpret, and share that result through software.
That is where tools like cloud analytics and artificial intelligence enter the picture. In this context, artificial intelligence, or AI, means software trained to help interpret patterns in data, while cloud systems allow information to be processed and accessed beyond the device itself. For users, the practical effect can be a simpler workflow and potentially faster guidance.
A UK example: PocDoc and heart screening
The article highlights Cambridge-based PocDoc as an example of how this model is being built in practice. Its platform combines app-based diagnostics with proprietary microfluidic assay tests, using a cloud-based AI system called HUESnap.
Microfluidic assays work a bit like a miniaturized plumbing network for biology: tiny channels guide very small liquid samples through a test so chemical signals can be measured quickly. Shrinking the process in this way can help make tests portable and practical for settings outside a full laboratory.
Manufacturing and deployment beyond the lab
Scaling a diagnostic idea into a real healthcare service requires manufacturing, distribution, and dependable supply, not just clever software. The article says Europlaz has supported PocDoc in expanding its UK-based manufacturing capabilities, underscoring that production capacity is now part of the innovation story.
PocDoc's Healthy Heart Check has already been rolled out across the UK, from Edinburgh to Cornwall, through pharmacies, the National Health Service, and other healthcare providers. That broad deployment matters because point-of-care tests only achieve their promise when they can reach ordinary care settings, not just pilot programs.
Reaching underserved communities
Another theme in the story is accessibility. The Healthy Heart Check has also been used in underserved UK communities and in high-footfall locations such as football stadiums, bringing screening into places where people already gather rather than expecting them to come to a hospital.
That approach reflects one of the most important ideas in PoC diagnostics: meet patients where they are. For screening programs especially, convenience can be the difference between a test that exists on paper and one that people actually take.
Why This Matters
The bigger significance of point-of-care diagnostics is not just speed. It is the possibility of shifting parts of healthcare from a centralized, appointment-heavy system to one that is more distributed, more preventive, and easier to access during everyday life.
For chronic conditions and major disease screening, that could mean earlier detection, quicker triage, and fewer missed opportunities for intervention. The trend also suggests diagnostics will increasingly be judged not only by analytical performance, but by whether they are easy to manufacture, simple to use, and connected to the digital systems that clinicians and patients already rely on.
The next phase will likely hinge on how well companies and healthcare systems integrate these tests into routine care, especially for populations that have been hardest to reach. If the field can pair reliable science with practical deployment, point-of-care diagnostics may become less of a special category and more of an everyday front door to healthcare.